Document is current

Article History

Received: 21 August 2019

Accepted: 20 March 2020

First Online: 2 April 2020

Compliance with ethical standards

:

: IK declares a research grant from Astellas (unrelated to the current study). Stock ownership—Teva Pharmaceutical. Honoraria from Merck Sharp & Dohme (MSD), Bristol-Myers Squibb and Janssen. Consulting or advisory role from Merck Sharp & Dohme (MSD). MO declares honoraria from Jannsen and Astellas; Travel expenses from Jannsen. CC declares consulting or advisory role for Merck, EMD Serono, Pfizer, Novartis, Bayer, Bristol-Myers Squibb and Astra Zeneca; Honoraria from Janssen; Research funding (unrelated to the current study) from Eisai, Astellas, Janssen, Astra Zeneca and Roche; Travel expenses from Sanofi Grenzyme and Amgen. DB declares consulting or advisory role for Bristol-Myers Squibb (Inst), Pfizer, AbbVie; Honoraria from AstraZeneca, Ipsen, Amgen and Janssen. NMR declares consulting or advisory role for Astellas Pharma and Pfizer; Honoraria from AstraZeneca, Eisai, Ipsen, Merck, Novartis and Roche. RM and KK declare no conflict of interest.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

: For this retrospective study, formal consent was not required by the Ottawa Health Science Network Research Ethics Board.